Acute myeloid leukemia (AML), an aggressive and often fatal blood cancer, has long resisted a class of drugs called ...
By combining proteasome inhibitors with a second drug that disables one of two backup survival pathways, the team was able to ...
Coinbase bought the UpOnly NFT for $25 million, enabling it to make Cobie “perform like a monkey” in a revival of the ...
Researchers used an 8-protein prognostic score termed the leukemia inflammatory risk score (LIRS) to identify inflammatory proteins with newly diagnosed AML.
IDH1 mutations in MDS are crucial for guiding therapy decisions, offering one of the few targetable mutations in this disease ...
Addition of TUS to VEN+AZA achieves CR/CRh responses in all (6/6, 100%) patients treated at the higher dose levels of 80 mg and 120 mg TUS, ...
Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML - ...
A systematic review finds AML patients receiving anthracycline remission induction therapy face a significant heart failure ...
- KOMET-001 in R/R NPM1-m AML met its primary endpoint with ziftomenib monotherapy demonstrating significant clinical benefit and deep responses - - Consistent activity across pre-specified subgroups, ...
– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3 mutations occur in approximately 30% of ...
Eastern Bank PLC (EBL) organized a day-long BAMLCO conference at its head office in Dhaka today, aimed at enhancing knowledge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback